Neuroendocrine Neoplasm of Lung Clinical Trial
Official title:
Risk Factors for Neuroendocrine Neoplasms: a Case-control Study Based on a Record Linkage of Registry and Claims Data
NCT number | NCT06282016 |
Other study ID # | BKR-2024-001 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 2024 |
Est. completion date | July 2025 |
Recent studies show an increase in neuroendocrine neoplasms, especially for the digestive tract. Previous studies suggest various risk factors that were observed for various tumor sites, e.g. a family history of cancer, tobacco and alcohol consumption as well as metabolic disorders including diabetes and obesity. A risk factor that has been little studied to date is depressive disorders, which could increase the risk of neuroendocrine neoplasms either independently or through associated risk behaviors and/or antidepressant medication. The aim of this study is to identify risk factors for neuroendocrine neoplasms based on a case-control study in order to better understand the increase of neuroendocrine neoplasms in recent decades. The study is based on a record linkage of data from the Bavarian Cancer Registry and data from the Bavarian Association of Statutory Health Insurance Accredited Physicians. While the data from the Bavarian Cancer Registry enables the identification of neuroendocrine neoplasms on the basis of histopathological findings and thus is the basis for selecting cases, the claims data from the Bavarian Association of Statutory Health Insurance Accredited Physicians provides the source population as well data on diagnoses and thus enables the investigation of risk factors.
Status | Not yet recruiting |
Enrollment | 7200 |
Est. completion date | July 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Resident in Bavaria for the years 2020 and 2021 Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bavarian Cancer Registry | Bavarian Association of Statutory Health Insurance Accredited Physicians |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Depression/Persistent mood disorder | Assured ICD-10 diagnosis F32, F33, or F34 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Obesity | Assured ICD-10 diagnosis E65 or E66 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Metabolic syndrome | At least three assured ICD-10 diagnoses out of five diagnoses groups (E66, E78.0, E78.1, I10, and E10-E14/R73), in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Previous malignant neoplasm | Documented malignant neoplasm (ICD-10 diagnosis C00-C97 excluding C44) in the Bavarian Cancer Registry | Previous to the NEN diagnosis for cases and matched controls | |
Primary | Alcohol buse | Assured ICD-10 diagnosis F10 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Diabetes | Assured ICD-10 diagnosis out of the diagnoses group E10-E14 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Ulcerative colitis | Assured ICD-10 diagnosis K51 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Crohn disease | Assured ICD-10 diagnosis K50 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Allergic rhinitis | Assured ICD-10 diagnosis J30.0 or J30.4 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Primary | Asthma | Assured ICD-10 diagnosis J45 in at least two out of four consecutive quarters | Two years previous to the NEN diagnosis for cases and matched controls | |
Secondary | Area deprivation | Area deprivation of the residence municipality (in quintiles) based on the Bavarian Index of Multiple Deprivation according to Maier, Fairburn & Mielck (2011, DOI: 10.1055/s-0031-1280846) | At the time of the NEN diagnosis for cases and matched controls |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03033186 -
Everolimus TDM to Predict Long Term Toxicity
|
N/A | |
Completed |
NCT03095274 -
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
|
Phase 2 |